Document Type : Case Report

Authors

1 Department of Flow Cytometry, Takhte Tavous Pathobiology Laboratory, Tehran, Iran Department of Clinical Laboratory Sciences, School of Allied Medical Sciences, Guilan University of Medical Sciences, Langeroud, Iran

2 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Dentistery student, Islamic Azad University, Tehran dental blanch

4 Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran

5 Applied Microbiology Research Center, Systems Biology and Prognosis Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

6 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Department of Flow Cytometry, Rasad Pathobiology and Genetic Laboratory, Tehran, IranTehran, Iran

Abstract

Background: Helicobacter pylori is a gram-negative spirochete that usually affects the gastric mucosa and has a prevalence of more than 50% of people worldwide. It has been revealed that Helicobacter pylori infection is not only associated with chronic gastritis and peptic ulcers, but also with some hematologic disorders such as immune thrombocytopenia, iron deficiency anemia and gastric mucosa-associated lymphoid tissue lymphoma. Immune thrombocytopenia is an acquired autoimmune disorder with low platelet count due to devastation of autoantibody-coated platelets.
Case report: In the present study, it was reported an Iranian patient with severe immune thrombocytopenia (platelet count 1×109/L) and Helicobacter pylori infection who achieved a long lasting platelet recovery after Helicobacter pylori eradication therapy. The patient was followed up for two years and no failure in platelet response was observed.
Conclusion: Accordingly, Helicobacter pylori treatment is not only useful in immune thrombocytopenia patients with mild and moderate thrombocytopenia but also may be beneficial in severe cases of immune thrombocytopenia.

Keywords

  1. Lamb A, Chen LF. Role of the Helicobacter pylori‐Induced inflammatory response in the development of gastric cancer. J Cell Biochem 2013; 114(3):491-7. doi: 10.1002/jcb.24389.
  2. Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The role of Helicobacter pylori infection in hematological disorders. Eur J Intern Med 2013; 24(8):685-90. doi: 10.1016/j.ejim.2013.02.011.
  3. Rahimian G, Bagheri N, Gholipour A, Shirzad H. The effect of TLR4 asp299gly polymorphism on IL-6 and IL-18 expression in H.pylori infected patients. JKUMS 2016; 23 (6): 703-713
  4. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood 2017; 129(21):2829-35. doi: 10.1182/blood-2017-03-754119.
  5. Payandeh M, Sohrabi N, Zare ME, Kansestani AN, Hashemian AH. Platelet count response to Helicobacter pylori eradication in Iranian patients with idiopathic thrombocytopenic purpura. Mediterr J Hematol Infect Dis 2012; 4(1):e2012056. doi: 10.4084/MJHID.2012.056.
  6. Payandeh M, Raeisi D, Sohrabi N, Zare ME, Kansestani AN, Keshavarz N, et al. Poor platelet count response to Helicobacter pylori eradication in patients with severe idiopathic thrombocytopenic purpura. Int J Hematol Oncol Stem Cell Res 2013; 7(3):9-14.
  7. Stasi R, Provan D. Helicobacter pylori and Chronic ITP. Hematology Am Soc Hematol Educ Program 2008; 206-11. doi: 10.1182/asheducation-2008.1.206.
  8. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113(6):1231-40. doi: 10.1182/blood-2008-07-167155.
  9. Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 2005; 118(4):414-9. doi: 10.1016/j.amjmed.2004.09.014.